SEMABIZ, Inc. | ChosaReport.com

日本と海外の市場調査レポート＆サービスを取り扱っております。

免疫療法薬市場 – 2029年までの世界予測

Immunotherapy Drugs Market - Global Forecast To 2029

免疫療法薬市場 - 種類別の（mAb、チェックポイント阻害剤、インターフェロン、がんワクチン）、用途（がん、自己免疫、炎症、血液学、神経学）、投与経路（静脈内、皮下）、エンドユーザー、市場規模、シェアおよび動向 - 2029年までの世界予測
Immunotherapy Drugs Market Size, Share & Trends by Type (mAb, Checkpoint Inhibitor, Interferon, Cancer Vaccine), Application (Cancer, Autoimmune, Inflammatory, Hematology, Neurology), Route of Administration (Intravenous, Subcutaneous), End User - Global Forecast to 2029
出版年月2024年7月
ページ数335
図表数394
価格タイプシングルユーザライセンス
価格USD 4,950
種別英文調査報告書

Report Overview

Immunotherapy drugs are designed to enhance the immune response or modulate the immune system’s regulatory mechanisms, thereby enabling the body to effectively target and eliminate disease-causing agents or cellsThe immunotherapy drugs market is projected to grow from USD 285.3 billion in 2024 to USD 580.6 billion by 2029, reflecting a compound annual growth rate (CAGR) of 15.3%. This growth is driven by technological advancements in antibody engineering, increasing demand for antibody therapies in clinical cancer treatment, and a growing preference for personalized medicines and targeted therapies. However, the market faces challenges such as the complexities involved in developing antibody therapeutics.

免疫療法薬市場 - 2029年までの世界予測

The Antibody drugs segment maintains major market share in the forecast period.

Based on type, the immunotherapy drugs market is divided into antibody drugs, inhibitor drugs, interferons & interleukins, cancer vaccines, and other immunotherapy drugs, which include oncolytic virus therapy and t-cell therapy. Antibody drugs hold the major market share. Increasing cancer incidence, the growing adoption of biological therapies, heightened investment in R&D, and supportive government policies are anticipated to propel market growth.

The Cancer segment is anticipated to dominate Immunotherapy Drugs Market through 2023-2029.

Based on applications, the immunotherapy drugs market is divided into cancer, autoimmune & inflammatory diseases, hematology, osteology, neurology, and other applications, including ophthalmology, dermatology, and cardiovascular diseases. Cancer commanded the largest market share in 2023. Elevated cancer rates, increased adoption of biological therapies, substantial R&D investment, and favorable government policies are expected to drive market growth during the forecast period. Companies in the immunotherapy drugs sector are exemplifying innovation through the development of new therapies, strategic collaborations, and enhanced spending on clinical research to explore immunotherapy treatments for cancer. These efforts aim to boost the immune system’s capability to fight cancer, offering new hope and improved patient outcomes.

免疫療法薬市場 - 2029年までの世界予測 ecosystem

The Intravenous Route segment is anticipated to grow at the fastest pace throughout the forecast period.

Based on the route of administration, the immunotherapy drugs market is broadly segmented into intravenous, subcutaneous, and other routes of administration (intravitreal and intramuscular). In 2023, the intravenous route of administration segment accounted for the largest share of the immunotherapy drugs market. This segment is also expected to grow at the highest CAGR during the forecast period. The large share and high growth rate are attributed to the growing preference for intravenous routes owing to its direct delivery into the bloodstream, ensuring rapid and consistent therapeutic effects for several conditions, including cancer and autoimmune diseases.

Hospitals segment generated the highest revenue in 2024 in the market.

Based on end users, the immunotherapy drugs market is broadly segmented into hospitals, long-term care facilities, and other end users (specialty care centers). In 2023, the hospitals segment commanded the largest share of the immunotherapy drugs market. Hospitals extensively use mAbs for their targeted therapy, rapid diagnostic applications, and efficacy in treating several disease indications, including cancer, autoimmune disorders, and infectious diseases.

The North America accounted for the largest share in the immunotherapy drugs market.

In 2023, North America accounted for the largest share of the global immunotherapy drugs market. The growth in the North American market can be attributed to rising immunotherapy research, the expansion of the healthcare sector, growing cancer prevalence, and the increasing approval and adoption of immunotherapy drugs for treating cancer and other chronic diseases. North America has witnessed significant growth in medical research advancements, growing clinical trials, and the developing biopharmaceutical industry. With increased research-driven activities and a high prevalence of cancer and chronic diseases, the demand for immunotherapies in North America is expected to rise significantly.

免疫療法薬市場 - 2029年までの世界予測 region

Breakdown of supply-side primary interviews by company type, designation, and region:

  • By Respondent: Supply Side (70%), Demand side (30%)
  • By Designation: C-level (55%), Director-level (20%), and Others (25%)
  • By Region: North America (50%), Europe (20%), AsiaPacific (20%), and Rest of the World(10%)

List of Companies Profiled in the Report

  • Merck & Co., Inc. (US)
  • Johnson & Johnson Services, Inc. (US)
  • F. Hoffman-La Roche Ltd. (Switzerland)
  • Pfizer Inc. (US)
  • AstraZeneca (UK)
  • Novartis AG (Switzerland)
  • Amgen Inc. (US)
  • Gilead Sciences, Inc. (UK)
  • Bristol-Myers Squibb Company (US)
  • Eli Lilly and Company (US)
  • Sanofi (France)
  • Takeda Pharmaceutical Company Limited (Japan)
  • Teva Pharmaceutical Industries Ltd (Israel)
  • GSK PLC (US)
  • Abbvie Inc. (US)

Research Coverage

This report studies the Immunotherapy Drugs market based on type, application, route of administration, end user, and region. The report also analyzes factors (such as drivers, restraints, opportunities, and challenges) affecting the market growth. It evaluates the opportunities and challenges in the market for stakeholders and provides details of the competitive landscape for market leaders. The report also studies micro markets with respect to their growth trends, prospects, and contributions to the total Immunotherapy Drugs market. The report forecasts the revenue of the market segments with respect to four major regions.

Reasons to Buy the Report:

The report provides insights on the following pointers:

  • Market Drivers: The key factors driving the overall market growth are technological advancements in antibody engineering, Increased demand for antibody therapies in clinical cancer treatment, and Growing demand for personalized medicines and targeted therapies
  • Product Development/Innovation: Detailed insights on upcoming technologies, research & development activities, and new product launches in the Immunotherapy Drugs market.
  • Market Penetration: Comprehensive information on Immunotherapy Drugs offered by the top 15 players in the market. The report analyzes the Immunotherapy Drugs market by Type, Application, Route of Administration, End User and Region
  • Market Development: Comprehensive information about lucrative emerging markets. The report analyzes the markets for various products/types of Immunotherapy Drugs across key geographic regions.
  • Market Diversification: Exhaustive information about untapped geographies, recent developments, and investments in the Immunotherapy Drugs market
  • Competitive Assessment: In-depth assessment of market shares and strategies of the leading players in the Immunotherapy Drugs market

Table of Contents

1            INTRODUCTION            29

1.1         STUDY OBJECTIVES      29

1.2         MARKET DEFINITION   29

1.2.1      INCLUSIONS & EXCLUSIONS     30

1.3         STUDY SCOPE  30

1.3.1      SEGMENTS COVERED   30

1.3.2      REGIONS COVERED      31

1.3.3      YEARS CONSIDERED     31

1.3.4      CURRENCY CONSIDERED          32

1.3.5      UNITS CONSIDERED     32

1.4         STAKEHOLDERS            32

1.5         SUMMARY OF CHANGES            32

1.5.1      RECESSION IMPACT      33

2            RESEARCH METHODOLOGY     34

2.1         RESEARCH DATA           34

2.1.1      SECONDARY DATA       34

2.1.1.1   Objectives of secondary research     35

2.1.2      PRIMARY DATA 35

2.1.2.1   Breakdown of primaries     36

2.2         MARKET ESTIMATION METHODOLOGY            36

2.2.1      COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)       37

2.2.2      INSIGHTS FROM PRIMARY EXPERTS      38

2.3         MARKET GROWTH RATE PROJECTIONS             39

2.4         DATA TRIANGULATION             41

2.5         STUDY ASSUMPTIONS  42

2.6         RISK ANALYSIS 42

2.7         IMPACT OF ECONOMIC RECESSION ON IMMUNOTHERAPY DRUGS MARKET            42

3            EXECUTIVE SUMMARY 44

4            PREMIUM INSIGHTS      48

4.1         IMMUNOTHERAPY DRUGS MARKET OVERVIEW             48

4.2         NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE AND COUNTRY (2023)           49

4.3         NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,

2024 VS. 2029 (USD BILLION)      50

5            MARKET OVERVIEW     51

5.1         INTRODUCTION            51

5.2         MARKET DYNAMICS     51

5.2.1      DRIVERS            52

5.2.1.1   Technological advancements in antibody engineering  52

5.2.1.2   Increasing demand for antibody therapeutics in clinical cancer treatment 53

5.2.1.3   Growing demand for personalized medicines and targeted therapies        54

5.2.2      RESTRAINTS     54

5.2.2.1   Stringent regulatory approval process for immunotherapy drugs 54

5.2.2.2   High cost of monoclonal antibody therapeutics            55

5.2.3      OPPORTUNITIES           56

5.2.3.1   Rising number of approvals for CAR T-cell therapies   56

5.2.3.2   Increasing collaborations among pharmaceutical companies, CROs, CDMOs, and academic institutes             57

5.2.4      CHALLENGES   58

5.2.4.1   Complexities in development of antibody therapeutics 58

5.3         PORTER’S FIVE FORCES ANALYSIS         59

5.3.1      THREAT OF NEW ENTRANTS    60

5.3.2      THREAT OF SUBSTITUTES         60

5.3.3      BARGAINING POWER OF SUPPLIERS     60

5.3.4      BARGAINING POWER OF BUYERS           60

5.3.5      INTENSITY OF COMPETITIVE RIVALRY 60

5.4         KEY STAKEHOLDERS & BUYING CRITERIA          61

5.4.1      KEY STAKEHOLDERS IN BUYING PROCESS         61

5.4.2      KEY BUYING CRITERIA 61

5.5         VALUE CHAIN ANALYSIS            62

5.6         SUPPLY CHAIN ANALYSIS          63

5.7         PRICING ANALYSIS        64

5.7.1      AVERAGE SELLING PRICE OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER 64

5.7.2     AVERAGE COST RANGE OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER, 2021–2023          65

5.7.3      INDICATIVE PRICE OF ANTIBODY THERAPEUTICS, BY ROUTE OF ADMINISTRATION         66

5.7.4      INDICATIVE PRICE OF IMMUNOTHERAPY DRUGS, BY REGION  67

5.8         ECOSYSTEM ANALYSIS 67

5.8.1      ROLE IN ECOSYSTEM (SUPPLY AND DEMAND SIDES)    68

5.9         PATENT ANALYSIS        70

5.10       TECHNOLOGY ANALYSIS           71

5.10.1    KEY TECHNOLOGIES    71

5.10.1.1 Gene editing        71

5.10.1.2 High-throughput screening              71

5.10.1.3 Next-generation sequencing            71

5.10.2    COMPLEMENTARY TECHNOLOGIES     72

5.10.2.1 Nanotechnology  72

5.10.2.2 Artificial intelligence          72

5.11       INVESTMENT & FUNDING SCENARIO    73

5.11.1    MAJOR INVESTMENTS AND FUNDING  73

5.11.2    OTHER INVESTMENTS AND FUNDING  79

5.12       KEY CONFERENCES & EVENTS, 2024–2025           81

5.13       CASE STUDY ANALYSIS 82

5.13.1    CASE STUDY 1: EFFICACY OF KEYTRUDA IN CANCER TREATMENT              82

5.13.2    CASE STUDY 2: EFFECTIVE USE OF LYNPARZA IN PROSTATE CANCER TREATMENT    83

5.13.3    CASE STUDY 3: CLINICAL TRIALS OF ORPATHYS (SAVOLITINIB)              83

5.14       REGULATORY LANDSCAPE       84

5.14.1    REGULATORY ANALYSIS            85

5.14.1.1 North America     85

5.14.1.1.1            US         85

5.14.1.1.2            Canada  86

5.14.1.2 Europe  86

5.14.1.2.1            Germany             86

5.14.1.2.2            UK         87

5.14.1.2.3            Rest of Europe     87

5.14.1.3 Asia Pacific          88

5.14.1.3.1            China     88

5.14.1.3.2            Japan     88

5.14.1.3.3            South Korea        89

5.14.1.3.4            Australia 89

5.14.2    REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS          90

5.14.2.1 North America     90

5.14.2.2 Europe  90

5.14.2.3 Asia Pacific          91

5.14.2.4 Latin America      92

5.14.2.5 Middle East & Africa          92

6            IMMUNOTHERAPY DRUGS MARKET, BY TYPE   93

6.1         INTRODUCTION            94

6.2         ANTIBODY DRUGS        94

6.2.1      ROBUST CLINICAL PIPELINE OF ANTIBODY THERAPEUTICS TO SUPPORT MARKET GROWTH    94

6.3         INHIBITOR DRUGS        98

6.3.1      INCREASED FOCUS ON DEVELOPMENT OF TARGET MEDICINES AND COMBINATION THERAPIES TO FUEL MARKET GROWTH            98

6.4         INTERFERONS & INTERLEUKINS            101

6.4.1      INCREASED FOCUS ON R&D AND DEVELOPMENT OF NEW IMMUNOTHERAPY DRUGS TO AUGMENT MARKET GROWTH   101

6.5         CANCER VACCINES       105

6.5.1      RISING FOCUS ON RESEARCH ACTIVITIES AND CLINICAL TRIALS TO SPUR MARKET GROWTH           105

6.6         OTHER IMMUNOTHERAPY DRUGS        108

7            IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION 112

7.1         INTRODUCTION            113

7.2         CANCER             113

7.2.1      LARGE R&D SPENDING AND HIGH GOVERNMENT INVESTMENTS TO DRIVE MARKET 113

7.3         AUTOIMMUNE & INFLAMMATORY DISEASES    117

7.3.1      ADVANCEMENTS IN MOLECULAR ENGINEERING AND INTRODUCTION OF BIOLOGICAL DRUGS TO PROPEL MARKET GROWTH              117

7.4         HEMATOLOGY 120

7.4.1      INCREASED R&D IN CELL-BASED THERAPIES, MONOCLONAL ANTIBODIES, AND IMMUNE CHECKPOINT INHIBITORS TO AID MARKET GROWTH          120

7.5         OSTEOLOGY    124

7.5.1      GROWING INCIDENCE OF OSTEOPOROSIS-RELATED FRACTURES TO DRIVE MARKET 124

7.6         NEUROLOGY    127

7.6.1      ADVANCEMENTS IN NEUROLOGICAL DRUG DEVELOPMENT TO BOOST MARKET GROWTH        127

7.7         OTHER APPLICATIONS 130

8            IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION              134

8.1         INTRODUCTION            135

8.2         INTRAVENOUS ROUTE OF ADMINISTRATION   135

8.2.1      DIRECT DELIVERY OF THERAPEUTIC DOSAGE TO PROPEL MARKET GROWTH          135

8.3         SUBCUTANEOUS ROUTE OF ADMINISTRATION             139

8.3.1      ENHANCED PATIENT ADHERENCE AND LOW HEALTHCARE COSTS TO AID MARKET GROWTH 139

8.4         OTHER ROUTES OF ADMINISTRATION 142

9            IMMUNOTHERAPY DRUGS MARKET, BY END USER        146

9.1         INTRODUCTION            147

9.2         HOSPITALS       147

9.2.1      AVAILABILITY OF ADVANCED HEALTHCARE INFRASTRUCTURE AND EXPERTISE TO AUGMENT MARKET GROWTH   147

9.3         LONG-TERM CARE FACILITIES 151

9.3.1      SPECIALIZED CARE AND CONTINUOUS MONITORING FOR PATIENTS WITH CHRONIC HEALTH CONDITIONS TO DRIVE MARKET       151

9.4         OTHER END USERS        154

10          IMMUNOTHERAPY DRUGS MARKET, BY REGION            158

10.1       INTRODUCTION            159

10.2       NORTH AMERICA          159

10.2.1    NORTH AMERICA: RECESSION IMPACT 162

10.2.2    US         163

10.2.2.1 US to dominate North American immunotherapy drugs market during forecast period    163

10.2.3    CANADA            165

10.2.3.1 Rising government initiatives for research on regenerative medicine to drive market   165

10.3       EUROPE             167

10.3.1    EUROPE: RECESSION IMPACT   170

10.3.2    GERMANY         170

10.3.2.1 Increasing investments in healthcare research to fuel market growth        170

10.3.3    UK         172

10.3.3.1 Favorable government initiatives and high R&D investments to propel market growth   172

10.3.4    FRANCE             175

10.3.4.1 Increasing adoption of immunotherapy drugs and growing focus on healthcare R&D to augment market growth      175

10.3.5    ITALY   177

10.3.5.1 Strong focus on clinical research and stringent government regulations to propel market growth     177

10.3.6    SPAIN   179

10.3.6.1 Favorable government initiatives to spur market growth            179

10.3.7    REST OF EUROPE           181

10.4       ASIA PACIFIC    183

10.4.1    ASIA PACIFIC: RECESSION IMPACT        187

10.4.2    CHINA  187

10.4.2.1 Less-stringent regulatory framework and high incidence of cancer to drive market              187

10.4.3    JAPAN  190

10.4.3.1 Rising geriatric population and increasing government support to augment market growth   190

10.4.4    INDIA   192

10.4.4.1 Increasing prevalence of cancer and rising government healthcare investments to aid market growth              192

10.4.5    SOUTH KOREA 194

10.4.5.1 Strong biopharmaceutical sector and favorable government initiatives to support market growth     194

10.4.6    AUSTRALIA       196

10.4.6.1 High prevalence of cancer and increased expenditure on health services to propel market growth     196

10.4.7    REST OF ASIA PACIFIC  198

10.5       LATIN AMERICA             200

10.5.1    LATIN AMERICA: RECESSION IMPACT   202

10.5.2    BRAZIL 203

10.5.2.1 Developed healthcare infrastructure and unified public health system to fuel market growth     203

10.5.3    REST OF LATIN AMERICA          205

10.6       MIDDLE EAST  208

10.6.1    MIDDLE EAST: RECESSION IMPACT       210

10.6.2    GCC COUNTRIES           210

10.6.2.1 Saudi Arabia        212

10.6.2.1.1            Increasing focus on R&D and growing government support to spur market growth     212

10.6.2.2 UAE      215

10.6.2.2.1            Technological advancements and increased government focus on healthcare to support market growth              215

10.6.2.3 Rest of GCC Countries      217

10.6.3    REST OF MIDDLE EAST 219

10.7       AFRICA 221

10.7.1    INCREASING HEALTHCARE FUNDING AND RISING INCIDENCE OF CANCER TO DRIVE MARKET     221

10.7.2    AFRICA: RECESSION IMPACT     224

11          COMPETITIVE LANDSCAPE       225

11.1       INTRODUCTION            225

11.2       KEY PLAYER STRATEGY/RIGHT TO WIN             225

11.2.1    OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOTHERAPY DRUGS MARKET     225

11.3       REVENUE ANALYSIS      227

11.4       MARKET SHARE ANALYSIS         227

11.5       COMPANY EVALUATION MATRIX: KEY PLAYERS, 2023   229

11.5.1    STARS  229

11.5.2    EMERGING LEADERS    229

11.5.3    PERVASIVE PLAYERS     229

11.5.4    PARTICIPANTS 230

11.5.5    COMPANY FOOTPRINT: KEY PLAYERS, 2023      231

11.5.5.1 Company footprint            231

11.5.5.2 Type footprint     232

11.5.5.3 Application footprint         233

11.5.5.4 Route of administration footprint     234

11.5.5.5 Region footprint  235

11.6       COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2023          236

11.6.1    PROGRESSIVE COMPANIES       236

11.6.2    RESPONSIVE COMPANIES          236

11.6.3    DYNAMIC COMPANIES 236

11.6.4    STARTING BLOCKS       236

11.6.5    COMPETITIVE BENCHMARKING: STARTUPS/SMES, 2023             238

11.7       COMPANY VALUATION & FINANCIAL METRICS 241

11.8       BRAND/PRODUCT COMPARISON          242

11.9       COMPETITIVE SCENARIO          243

11.9.1    PRODUCT APPROVALS 243

11.9.2    DEALS  244

11.9.3    OTHER DEVELOPMENTS           244

12          COMPANY PROFILES    245

12.1       KEY PLAYERS   245

12.1.1    MERCK & CO., INC.         245

12.1.1.1 Business overview 245

12.1.1.2 Products/Services/Solutions offered 246

12.1.1.3 Recent developments         247

12.1.1.3.1            Product approvals 247

12.1.1.3.2            Deals     249

12.1.1.4 MnM view           250

12.1.1.4.1            Key strengths       250

12.1.1.4.2            Strategic choices  250

12.1.1.4.3            Weaknesses & competitive threats   250

12.1.2    JOHNSON & JOHNSON SERVICES, INC.  251

12.1.2.1 Business overview 251

12.1.2.2 Products/Services/Solutions offered 252

12.1.2.3 Recent developments         253

12.1.2.3.1            Product approvals 253

12.1.2.3.2            Deals     254

12.1.2.3.3            Expansions          255

12.1.2.4 MnM view           255

12.1.2.4.1            Key strengths       255

12.1.2.4.2            Strategic choices  255

12.1.2.4.3            Weaknesses & competitive threats   255

12.1.3    F. HOFFMANN-LA ROCHE LTD. 256

12.1.3.1 Business overview 256

12.1.3.2 Products/Services/Solutions offered 257

12.1.3.3 Recent developments         260

12.1.3.3.1            Product approvals 260

12.1.3.3.2            Deals     261

12.1.3.4 MnM view           261

12.1.3.4.1            Key strengths       261

12.1.3.4.2            Strategic choices  261

12.1.3.4.3            Weaknesses & competitive threats   261

12.1.4    ASTRAZENECA 262

12.1.4.1 Business overview 262

12.1.4.2 Products/Services/Solutions offered 263

12.1.4.3 Recent developments         265

12.1.4.3.1            Product approvals 265

12.1.4.3.2            Deals     267

12.1.4.3.3            Expansions          269

12.1.5    PFIZER INC.       270

12.1.5.1 Business overview 270

12.1.5.2 Products/Services/Solutions offered 271

12.1.5.3 Recent developments         273

12.1.5.3.1            Product approvals 273

12.1.5.3.2            Deals     274

12.1.6    AMGEN INC.      275

12.1.6.1 Business overview 275

12.1.6.2 Products/Services/Solutions offered 276

12.1.6.3 Recent developments         277

12.1.6.3.1            Product approvals 277

12.1.6.3.2            Expansions          278

12.1.7    NOVARTIS AG   279

12.1.7.1 Business overview 279

12.1.7.2 Products/Services/Solutions offered 280

12.1.7.3 Recent developments         281

12.1.7.3.1            Product approvals 281

12.1.7.3.2            Deals     282

12.1.8    ELI LILLY AND COMPANY          283

12.1.8.1 Business overview 283

12.1.8.2 Products/Services/Solutions offered 284

12.1.8.3 Recent developments         285

12.1.8.3.1            Product approvals 285

12.1.8.3.2            Deals     286

12.1.9    SANOFI 287

12.1.9.1 Business overview 287

12.1.9.2 Products/Services/Solutions offered 288

12.1.9.3 Recent developments         290

12.1.9.3.1            Product approvals 290

12.1.9.3.2            Deals     290

12.1.10  BRISTOL-MYERS SQUIBB COMPANY      292

12.1.10.1             Business overview 292

12.1.10.2             Products/Services/Solutions offered 293

12.1.10.3             Recent developments         295

12.1.10.3.1          Product approvals 295

12.1.10.3.2          Deals     299

12.1.11  GILEAD SCIENCES, INC. 300

12.1.11.1             Business overview 300

12.1.11.2             Products/Services/Solutions offered 301

12.1.11.3             Recent developments         301

12.1.11.3.1          Product approvals 301

12.1.11.3.2          Deals     302

12.1.11.3.3          Other developments          303

12.1.12  TAKEDA PHARMACEUTICAL COMPANY LIMITED          304

12.1.12.1             Business overview 304

12.1.12.2             Products/Services/Solutions offered 305

12.1.12.3             Recent developments         305

12.1.12.3.1          Product approvals 305

12.1.12.3.2          Deals     306

12.1.13  TEVA PHARMACEUTICAL INDUSTRIES LTD.     307

12.1.13.1             Business overview 307

12.1.13.2             Products/Services/Solutions offered 308

12.1.13.3             Recent developments         308

12.1.13.3.1          Deals     308

12.1.14  ABBVIE INC.      309

12.1.14.1             Business overview 309

12.1.14.2             Products/Services/Solutions offered 310

12.1.14.3             Recent developments         311

12.1.14.3.1          Product approvals 311

12.1.14.3.2          Deals     312

12.1.15  GSK PLC            313

12.1.15.1             Business overview 313

12.1.15.2             Products/Services/Solutions offered 314

12.1.15.3             Recent developments         315

12.1.15.3.1          Product approvals 315

12.1.15.3.2          Deals     317

12.1.15.3.3          Other developments          318

12.2       OTHER PLAYERS           319

12.2.1    IMMUNOCORE HOLDINGS PLC 319

12.2.2    ASTELLAS PHARMA INC.            320

12.2.3    GENMAB A/S    321

12.2.4    MACROGENICS, INC.     321

12.2.5    FERRING BV      322

12.2.6    Y-MABS THERAPEUTICS, INC.   323

12.2.7    BIOGEN             324

12.2.8    KYOWA KIRIN CO., LTD.             325

12.2.9    SWEDISH ORPHAN BIOVITRUM AB        326

12.2.10  BOEHRINGER INGELHEIM INTERNATIONAL GMBH       327

13          APPENDIX         328

13.1       DISCUSSION GUIDE      328

13.2       KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL             331

13.3       CUSTOMIZATION OPTIONS      333

13.4       RELATED REPORTS       333

13.5       AUTHOR DETAILS         334

LIST OF TABLES

TABLE 1             IMMUNOTHERAPY DRUGS MARKET: INCLUSIONS & EXCLUSIONS    30

TABLE 2             IMMUNOTHERAPY DRUGS MARKET: RISK ANALYSIS     42

TABLE 3             GLOBAL INFLATION RATE PROJECTIONS, 2021–2028 (% GROWTH)         43

TABLE 4             IMMUNOTHERAPY DRUGS MARKET: IMPACT ANALYSIS              52

TABLE 5             NUMBER OF APPROVED PRODUCTS BY US FDA/EMA, 2015–2023      53

TABLE 6             APPROVED AUTOLOGOUS CAR T-CELL THERAPIES      56

TABLE 7             IMMUNOTHERAPY DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS          59

TABLE 8             AVERAGE COST RANGE OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER,

2021–2023          65

TABLE 9             INDICATIVE PRICE OF ANTIBODY THERAPEUTICS, BY ROUTE OF ADMINISTRATION   66

TABLE 10           INDICATIVE PRICE OF IMMUNOTHERAPY DRUGS, BY REGION              67

TABLE 11           IMMUNOTHERAPY DRUGS MARKET: ROLE IN ECOSYSTEM

(SUPPLY AND DEMAND SIDES) 68

TABLE 12           IMMUNOTHERAPY DRUGS MARKET: MAJOR INVESTMENTS AND FUNDING, JANUARY 2021–MAY 2024           73

TABLE 13           IMMUNOTHERAPY DRUGS MARKET: LIST OF KEY CONFERENCES & EVENTS, JANUARY 2024–DECEMBER 2025        81

TABLE 14           NORTH AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         90

TABLE 15           EUROPE: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         90

TABLE 16           ASIA PACIFIC: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         91

TABLE 17           LATIN AMERICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         92

TABLE 18           MIDDLE EAST & AFRICA: LIST OF REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS         92

TABLE 19           IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)           94

TABLE 20           IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (UNITS)             94

TABLE 21           ANTIBODY DRUGS MARKET, BY REGION, 2022–2029 (USD BILLION)           96

TABLE 22           NORTH AMERICA: ANTIBODY DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           96

TABLE 23           EUROPE: ANTIBODY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION) 96

TABLE 24           ASIA PACIFIC: ANTIBODY DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           97

TABLE 25           LATIN AMERICA: ANTIBODY DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           97

TABLE 26           MIDDLE EAST: ANTIBODY DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           97

TABLE 27           GCC COUNTRIES: ANTIBODY DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           98

TABLE 28           INHIBITOR DRUGS MARKET, 2022–2029 (USD BILLION) 99

TABLE 29           NORTH AMERICA: INHIBITOR DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           99

TABLE 30           EUROPE: INHIBITOR DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION) 100

TABLE 31           ASIA PACIFIC: INHIBITOR DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           100

TABLE 32           LATIN AMERICA: INHIBITOR DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           100

TABLE 33           MIDDLE EAST: INHIBITOR DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           101

TABLE 34           GCC COUNTRIES: INHIBITOR DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           101

TABLE 35           INTERFERONS & INTERLEUKINS MARKET, BY REGION, 2022–2029 (USD BILLION)      102

TABLE 36           NORTH AMERICA: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           102

TABLE 37           EUROPE: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           103

TABLE 38           ASIA PACIFIC: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           103

TABLE 39           LATIN AMERICA: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           104

TABLE 40           MIDDLE EAST: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           104

TABLE 41           GCC COUNTRIES: INTERFERONS & INTERLEUKINS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           104

TABLE 42           CANCER VACCINES MARKET, BY REGION, 2022–2029 (USD BILLION)           106

TABLE 43           NORTH AMERICA: CANCER VACCINES MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           106

TABLE 44           EUROPE: CANCER VACCINES MARKET, BY COUNTRY, 2022–2029 (USD BILLION)      106

TABLE 45           ASIA PACIFIC: CANCER VACCINES MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           107

TABLE 46           LATIN AMERICA: CANCER VACCINES MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           107

TABLE 47           MIDDLE EAST: CANCER VACCINES MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           107

TABLE 48           GCC COUNTRIES: CANCER VACCINES MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           108

TABLE 49           OTHER IMMUNOTHERAPY DRUGS MARKET, BY REGION,

2022–2029 (USD BILLION)           109

TABLE 50          NORTH AMERICA: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY, 2022–2029 (USD BILLION)             109

TABLE 51           EUROPE: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           109

TABLE 52           ASIA PACIFIC: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           110

TABLE 53           LATIN AMERICA: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           110

TABLE 54           MIDDLE EAST: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           110

TABLE 55           GCC COUNTRIES: OTHER IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           111

TABLE 56           IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)      113

TABLE 57           IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY REGION,

2022–2029 (USD BILLION)           114

TABLE 58           NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD BILLION)          114

TABLE 59           EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY,

2022–2029 (USD BILLION)           115

TABLE 60           ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD BILLION)          115

TABLE 61           LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD BILLION)          116

TABLE 62           MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY REGION, 2022–2029 (USD BILLION) 116

TABLE 63           GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR CANCER, BY COUNTRY, 2022–2029 (USD BILLION)          116

TABLE 64           IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2022–2029 (USD BILLION)         117

TABLE 65           NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)           118

TABLE 66           EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)           118

TABLE 67           ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)           119

TABLE 68           LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)           119

TABLE 69           MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY REGION, 2022–2029 (USD BILLION)           119

TABLE 70           GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR AUTOIMMUNE & INFLAMMATORY DISEASES, BY COUNTRY, 2022–2029 (USD BILLION)           120

TABLE 71           IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY REGION,

2022–2029 (USD BILLION)           121

TABLE 72           NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY,

BY COUNTRY, 2022–2029 (USD BILLION)             121

TABLE 73           EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)            122

TABLE 74           ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY,

BY COUNTRY, 2022–2029 (USD BILLION)             122

TABLE 75           LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY,

BY COUNTRY, 2022–2029 (USD BILLION)             123

TABLE 76           MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY, BY REGION, 2022–2029 (USD BILLION)  123

TABLE 77           GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR HEMATOLOGY,

BY COUNTRY, 2022–2029 (USD BILLION)             123

TABLE 78           IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY REGION,

2022–2029 (USD BILLION)           124

TABLE 79           NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY,

BY COUNTRY, 2022–2029 (USD BILLION)             125

TABLE 80           EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)  125

TABLE 81           ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY COUNTRY, 2022–2029 (USD BILLION)  125

TABLE 82           LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY,

BY COUNTRY, 2022–2029 (USD BILLION)             126

TABLE 83           MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY, BY REGION, 2022–2029 (USD BILLION)      126

TABLE 84           GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR OSTEOLOGY,

BY COUNTRY, 2022–2029 (USD BILLION)             126

TABLE 85           IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY REGION,

2022–2029 (USD BILLION)           127

TABLE 86           NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY,

BY COUNTRY, 2022–2029 (USD BILLION)             127

TABLE 87           EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION)  128

TABLE 88           ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY COUNTRY, 2022–2029 (USD BILLION)  128

TABLE 89           LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY,

BY COUNTRY, 2022–2029 (USD BILLION)             129

TABLE 90           MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY, BY REGION, 2022–2029 (USD BILLION)     129

TABLE 91           GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR NEUROLOGY,

BY COUNTRY, 2022–2029 (USD BILLION)             129

TABLE 92           IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY REGION,

2022–2029 (USD BILLION)           131

TABLE 93           NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION)            131

TABLE 94           EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2029 (USD BILLION)             132

TABLE 95           ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2029 (USD BILLION)             132

TABLE 96           LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS,

BY COUNTRY, 2022–2029 (USD BILLION)             133

TABLE 97           MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS,

BY REGION, 2022–2029 (USD BILLION)   133

TABLE 98           GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2022–2029 (USD BILLION)            133

TABLE 99           IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION,

2022–2029 (USD BILLION)           135

TABLE 100         IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD BILLION)    136

TABLE 101         NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)           136

TABLE 102         EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)           137

TABLE 103         ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)           137

TABLE 104         LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)           138

TABLE 105         MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD BILLION)           138

TABLE 106         GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR INTRAVENOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)           138

TABLE 107         IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 (USD BILLION)    139

TABLE 108         NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)           140

TABLE 109         EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)           140

TABLE 110         ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)           141

TABLE 111         LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)           141

TABLE 112         MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY REGION, 2022–2029 USD BILLION)           141

TABLE 113         GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR SUBCUTANEOUS ROUTE OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)           142

TABLE 114         IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD BILLION)          143

TABLE 115         NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)           143

TABLE 116         EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)              144

TABLE 117         ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)              144

TABLE 118         LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)           145

TABLE 119         MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY REGION, 2022–2029 (USD BILLION)              145

TABLE 120         GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR OTHER ROUTES OF ADMINISTRATION, BY COUNTRY, 2022–2029 (USD BILLION)           145

TABLE 121         IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION) 147

TABLE 122         IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY REGION,

2022–2029 (USD BILLION)           148

TABLE 123         NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS,

BY COUNTRY, 2022–2029 (USD BILLION)             148

TABLE 124         EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION)             149

TABLE 125         ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY COUNTRY, 2022–2029 (USD BILLION)     149

TABLE 126         LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS,

BY COUNTRY, 2022–2029 (USD BILLION)             150

TABLE 127         MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS, BY REGION, 2022–2029 (USD BILLION)        150

TABLE 128         GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR HOSPITALS,

BY COUNTRY, 2022–2029 (USD BILLION)             150

TABLE 129         IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD BILLION)         151

TABLE 130         NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD BILLION)              152

TABLE 131         EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD BILLION)           152

TABLE 132         ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD BILLION)           153

TABLE 133         LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD BILLION)              153

TABLE 134         MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY REGION, 2022–2029 (USD BILLION)   153

TABLE 135         GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR LONG-TERM CARE FACILITIES, BY COUNTRY, 2022–2029 (USD BILLION)              154

TABLE 136         IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS, BY REGION,

2022–2029 (USD BILLION)           154

TABLE 137         NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD BILLION)             155

TABLE 138         EUROPE: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD BILLION)             155

TABLE 139         ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD BILLION)             156

TABLE 140         LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD BILLION)             156

TABLE 141         MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS,

BY REGION, 2022–2029 (USD BILLION)   156

TABLE 142         GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET FOR OTHER END USERS,

BY COUNTRY, 2022–2029 (USD BILLION)             157

TABLE 143         IMMUNOTHERAPY DRUGS MARKET, BY REGION, 2022–2029 (USD BILLION) 159

TABLE 144         NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           160

TABLE 145         NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,

2022–2029 (USD BILLION)           161

TABLE 146         NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)            161

TABLE 147         NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           162

TABLE 148         NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           162

TABLE 149         US: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION) 163

TABLE 150         US: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION,

2022–2029 (USD BILLION)           164

TABLE 151         US: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           164

TABLE 152         US: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)      164

TABLE 153         CANADA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)      166

TABLE 154         CANADA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)    166

TABLE 155         CANADA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           167

TABLE 156         CANADA: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           167

TABLE 157         EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           168

TABLE 158         EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)      168

TABLE 159         EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)    169

TABLE 160         EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           169

TABLE 161         EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           169

TABLE 162         GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,

2022–2029 (USD BILLION)           171

TABLE 163         GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)    171

TABLE 164         GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           172

TABLE 165         GERMANY: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           172

TABLE 166         UK: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION) 173

TABLE 167         UK: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION,

2022–2029 (USD BILLION)           174

TABLE 168         UK: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           174

TABLE 169         UK: IMMUNOTHERAPY DRUGS THERAPEUTICS MARKET, BY END USER,

2022–2029 (USD BILLION)           174

TABLE 170         FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)      175

TABLE 171         FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)    176

TABLE 172         FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           176

TABLE 173         FRANCE: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           176

TABLE 174         ITALY: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)      177

TABLE 175         ITALY: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION,

2022–2029 (USD BILLION)           178

TABLE 176         ITALY: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           178

TABLE 177         ITALY: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           178

TABLE 178         SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)      179

TABLE 179         SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD MILLION)   180

TABLE 180         SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           180

TABLE 181         SPAIN: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           180

TABLE 182         REST OF EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,

2022–2029 (USD BILLION)           181

TABLE 183         REST OF EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)            182

TABLE 184         REST OF EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           182

TABLE 185         REST OF EUROPE: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           183

TABLE 186         ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           185

TABLE 187         ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,

2022–2029 (USD BILLION)           185

TABLE 188         ASIA PACIFIC: IMMUNOTHERAPY DRUGS, BY ROUTE OF ADMINISTRATION,

2022–2029 (USD BILLION)           186

TABLE 189         ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           186

TABLE 190         ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           187

TABLE 191         CHINA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)      188

TABLE 192         CHINA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)    189

TABLE 193         CHINA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           189

TABLE 194         CHINA: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           189

TABLE 195         JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)      190

TABLE 196         JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)    191

TABLE 197         JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           191

TABLE 198         JAPAN: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           191

TABLE 199         INDIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)      192

TABLE 200         INDIA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION,

2022–2029 (USD BILLION)           193

TABLE 201         INDIA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           193

TABLE 202         INDIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           193

TABLE 203         SOUTH KOREA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,

2022–2029 (USD BILLION)           194

TABLE 204         SOUTH KOREA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)            195

TABLE 205         SOUTH KOREA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           195

TABLE 206         SOUTH KOREA: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           196

TABLE 207         AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,

2022–2029 (USD BILLION)           196

TABLE 208         AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)            197

TABLE 209         AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           197

TABLE 210         AUSTRALIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           198

TABLE 211         REST OF ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,

2022–2029 (USD BILLION)           198

TABLE 212         REST OF ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)            199

TABLE 213         REST OF ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)            199

TABLE 214         REST OF ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           200

TABLE 215         LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           200

TABLE 216        LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,

2022–2029 (USD BILLION)           201

TABLE 217         LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)            201

TABLE 218         LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           202

TABLE 219         LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           202

TABLE 220         BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)      203

TABLE 221         BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)    204

TABLE 222        BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           204

TABLE 223         BRAZIL: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           205

TABLE 224         REST OF LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,

2022–2029 (USD BILLION)           206

TABLE 225         REST OF LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)      206

TABLE 226         REST OF LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)      207

TABLE 227         REST OF LATIN AMERICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)             207

TABLE 228         MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY REGION,

2022–2029 (USD BILLION)           208

TABLE 229         MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,

2022–2029 (USD BILLION)           208

TABLE 230         MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)            209

TABLE 231         MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           209

TABLE 232         MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           210

TABLE 233         GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY COUNTRY,

2022–2029 (USD BILLION)           210

TABLE 234         GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,

2022–2029 (USD BILLION)           211

TABLE 235         GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)            211

TABLE 236         GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           212

TABLE 237         GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           212

TABLE 238         SAUDI ARABIA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,

2022–2029 (USD BILLION)           213

TABLE 239         SAUDI ARABIA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)            214

TABLE 240         SAUDI ARABIA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           214

TABLE 241         SAUDI ARABIA: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           215

TABLE 242         UAE: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION) 216

TABLE 243         UAE: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2

022–2029 (USD BILLION)             216

TABLE 244         UAE: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           217

TABLE 245         UAE: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           217

TABLE 246         REST OF GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,

2022–2029 (USD BILLION)           218

TABLE 247         REST OF GCC COUNTRIES: IMMUNOTHERAPY DRUGS, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)            218

TABLE 248         REST OF GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)   219

TABLE 249         REST OF GCC COUNTRIES: IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2022–2029 (USD BILLION)          219

TABLE 250         REST OF MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY TYPE,

2022–2029 (USD BILLION)           220

TABLE 251         REST OF MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)      220

TABLE 252         REST OF MIDDLE EAST: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION, 2022–2029 (USD BILLION)      221

TABLE 253         REST OF MIDDLE EAST: IMMUNOTHERAPY DRUGS THERAPEUTICS MARKET,

BY END USER, 2022–2029 (USD BILLION)             221

TABLE 254         AFRICA: IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2022–2029 (USD BILLION)      222

TABLE 255         AFRICA: IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022–2029 (USD BILLION)    223

TABLE 256         AFRICA: IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2022–2029 (USD BILLION)           223

TABLE 257         AFRICA: IMMUNOTHERAPY DRUGS MARKET, BY END USER,

2022–2029 (USD BILLION)           224

TABLE 258         OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN IMMUNOTHERAPY DRUGS MARKET     225

TABLE 259         IMMUNOTHERAPY DRUGS MARKET: DEGREE OF COMPETITION 228

TABLE 260         IMMUNOTHERAPY DRUGS MARKET: TYPE FOOTPRINT              232

TABLE 261         IMMUNOTHERAPY DRUGS MARKET: APPLICATION FOOTPRINT      233

TABLE 262         IMMUNOTHERAPY DRUGS MARKET: ROUTE OF ADMINISTRATION FOOTPRINT 234

TABLE 263         IMMUNOTHERAPY DRUGS MARKET: REGION FOOTPRINT              235

TABLE 264         IMMUNOTHERAPY DRUGS MARKET: DETAILED LIST OF KEY STARTUPS/SMES           238

TABLE 265         IMMUNOTHERAPY DRUGS MARKET: COMPETITIVE BENCHMARKING

OF KEY START UPS/SMES          240

TABLE 266         IMMUNOTHERAPY DRUGS MARKET: PRODUCT APPROVALS,

JANUARY 2021–MAY 2024            243

TABLE 267         IMMUNOTHERAPY DRUGS MARKET: DEALS, JANUARY 2021–MAY 2024           244

TABLE 268         IMMUNOTHERAPY DRUGS MARKET: OTHER DEVELOPMENTS,

JANUARY 2021–MAY 2024            244

TABLE 269         MERCK & CO., INC.: COMPANY OVERVIEW         245

TABLE 270         MERCK & CO., INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED          246

TABLE 271         MERCK & CO., INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024           247

TABLE 272         MERCK & CO., INC.: DEALS, JANUARY 2021–MAY 2024     249

TABLE 273         JOHNSON & JOHNSON SERVICES, INC.: COMPANY OVERVIEW              251

TABLE 274         JOHNSON & JOHNSON SERVICES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED   252

TABLE 275         JOHNSON & JOHNSON SERVICES, INC.: PRODUCT APPROVALS,

JANUARY 2021–MAY 2024            253

TABLE 276         JOHNSON & JOHNSON SERVICES, INC.: DEALS, JANUARY 2021–MAY 2024           254

TABLE 277         JOHNSON & JOHNSON SERVICES, INC.: EXPANSIONS, JANUARY 2021–MAY 2024 255

TABLE 278         F. HOFFMANN-LA ROCHE LTD.: COMPANY OVERVIEW 256

TABLE 279         F. HOFFMANN-LA ROCHE LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED   257

TABLE 280         F. HOFFMANN-LA ROCHE LTD.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024            260

TABLE 281         F. HOFFMANN-LA ROCHE LTD.: DEALS, JANUARY 2021–MAY 2024      261

TABLE 282         ASTRAZENECA: COMPANY OVERVIEW  262

TABLE 283         ASTRAZENECA: PRODUCTS/SERVICES/SOLUTIONS OFFERED              263

TABLE 284         ASTRAZENECA: PRODUCT APPROVALS, JANUARY 2021–MAY 2024      265

TABLE 285         ASTRAZENECA: DEALS, JANUARY 2021–MAY 2024            267

TABLE 286         ASTRAZENECA: EXPANSIONS, JANUARY 2021–MAY 2024 269

TABLE 287         PFIZER INC.: COMPANY OVERVIEW       270

TABLE 288         PFIZER INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED              271

TABLE 289         PFIZER INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024              273

TABLE 290         PFIZER INC.: DEALS, JANUARY 2021–MAY 2024   274

TABLE 291         AMGEN INC.: COMPANY OVERVIEW      275

TABLE 292         AMGEN INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED              276

TABLE 293         AMGEN INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024              277

TABLE 294         AMGEN INC.: EXPANSIONS, JANUARY 2021–MAY 2024     278

TABLE 295         NOVARTIS AG: COMPANY OVERVIEW   279

TABLE 296         NOVARTIS AG: PRODUCTS/SERVICES/SOLUTIONS OFFERED              280

TABLE 297         NOVARTIS AG: PRODUCT APPROVALS, JANUARY 2021–MAY 2024      281

TABLE 298         NOVARTIS AG: DEALS, JANUARY 2021–MAY 2024             282

TABLE 299         ELI LILLY AND COMPANY: COMPANY OVERVIEW          283

TABLE 300         ELI LILLY AND COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED          284

TABLE 301         ELI LILLY AND COMPANY: PRODUCT APPROVALS, JANUARY 2021–MAY 2024 285

TABLE 302         ELI LILLY AND COMPANY.: DEALS, JANUARY 2021–MAY 2024              286

TABLE 303         SANOFI: COMPANY OVERVIEW 287

TABLE 304         SANOFI: PRODUCTS/SERVICES/SOLUTIONS OFFERED  288

TABLE 305         SANOFI: PRODUCT APPROVALS, JANUARY 2021–MAY 2024              290

TABLE 306         SANOFI: DEALS, JANUARY 2021–MAY 2024           290

TABLE 307         BRISTOL-MYERS SQUIBB COMPANY: COMPANY OVERVIEW              292

TABLE 308         BRISTOL-MYERS SQUIBB COMPANY: PRODUCTS/SERVICES/SOLUTIONS OFFERED   293

TABLE 309         BRISTOL-MYERS SQUIBB COMPANY: PRODUCT APPROVALS,

JANUARY 2021–MAY 2024            295

TABLE 310         BRISTOL-MYERS SQUIBB COMPANY: DEALS, JANUARY 2021–MAY 2024           299

TABLE 311         GILEAD SCIENCES, INC.: COMPANY OVERVIEW 300

TABLE 312         GILEAD SCIENCES, INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED          301

TABLE 313         GILEAD SCIENCES, INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024 301

TABLE 314         GILEAD SCIENCES, INC.: DEALS, JANUARY 2021–MAY 2024              302

TABLE 315         GILEAD SCIENCES, INC.: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024 303

TABLE 316         TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY OVERVIEW        304

TABLE 317         TAKEDA PHARMACEUTICAL COMPANY LIMITED:

PRODUCTS/SERVICES/SOLUTIONS OFFERED   305

TABLE 318         TAKEDA PHARMACEUTICAL COMPANY LIMITED: PRODUCT APPROVALS,

JANUARY 2021–MAY 2024            305

TABLE 319         TAKEDA PHARMACEUTICAL COMPANY LIMITED: DEALS, JANUARY 2021–MAY 2024            306

TABLE 320         TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY OVERVIEW        307

TABLE 321         TEVA PHARMACEUTICAL INDUSTRIES LTD.: PRODUCTS/SERVICES/SOLUTIONS OFFERED   308

TABLE 322         TEVA PHARMACEUTICAL INDUSTRIES LTD.: DEALS, JANUARY 2021–MAY 2024 308

TABLE 323         ABBVIE INC.: COMPANY OVERVIEW      309

TABLE 324         ABBVIE INC.: PRODUCTS/SERVICES/SOLUTIONS OFFERED              310

TABLE 325         ABBVIE INC.: PRODUCT APPROVALS, JANUARY 2021–MAY 2024              311

TABLE 326         ABBVIE INC.: DEALS, JANUARY 2021–MAY 2024  312

TABLE 327         GSK PLC: COMPANY OVERVIEW             313

TABLE 328         GSK PLC: PRODUCTS/SERVICES/SOLUTIONS OFFERED 314

TABLE 329         GSK PLC: PRODUCT APPROVALS, JANUARY 2021–MAY 2024              315

TABLE 330         GSK PLC: DEALS, JANUARY 2021–MAY 2024         317

TABLE 331         GSK PLC: OTHER DEVELOPMENTS, JANUARY 2021–MAY 2024              318

TABLE 332         IMMUNOCORE HOLDINGS PLC: COMPANY OVERVIEW 319

TABLE 333         ASTELLAS PHARMA INC.: COMPANY OVERVIEW             320

TABLE 334         GENMAB A/S: COMPANY OVERVIEW     321

TABLE 335         MACROGENICS, INC.: COMPANY OVERVIEW     321

TABLE 336         FERRING BV: COMPANY OVERVIEW      322

TABLE 337         Y-MABS THERAPEUTICS, INC.: COMPANY OVERVIEW    323

TABLE 338         BIOGEN: COMPANY OVERVIEW 324

TABLE 339         KYOWA KIRIN CO., LTD.: COMPANY OVERVIEW 325

TABLE 340         SWEDISH ORPHAN BIOVITRUM AB: COMPANY OVERVIEW              326

TABLE 341         BOEHRINGER INGELHEIM INTERNATIONAL GMBH: COMPANY OVERVIEW        327

LIST OF FIGURES

FIGURE 1           IMMUNOTHERAPY DRUGS MARKET: SEGMENTS COVERED              30

FIGURE 2           IMMUNOTHERAPY DRUGS MARKET: REGIONS COVERED              31

FIGURE 3           IMMUNOTHERAPY DRUGS MARKET: YEARS CONSIDERED              31

FIGURE 4           IMMUNOTHERAPY DRUGS MARKET: RESEARCH DESIGN              34

FIGURE 5           IMMUNOTHERAPY DRUGS MARKET: BREAKDOWN OF PRIMARIES        36

FIGURE 6           IMMUNOTHERAPY DRUGS MARKET SIZE ESTIMATION

(SUPPLY-SIDE ANALYSIS), 2023 36

FIGURE 7           MARKET SIZE ESTIMATION: COMPANY REVENUE ANALYSIS-BASED

ESTIMATION, 2023         37

FIGURE 8           MARKET SIZE VALIDATION FROM PRIMARY SOURCES  38

FIGURE 9           IMMUNOTHERAPY DRUGS MARKET: CAGR PROJECTIONS              40

FIGURE 10         IMMUNOTHERAPY DRUGS MARKET: ANALYSIS OF DEMAND-SIDE DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES        40

FIGURE 11         DATA TRIANGULATION METHODOLOGY         41

FIGURE 12         IMMUNOTHERAPY DRUGS MARKET, BY TYPE, 2024 VS. 2029 (USD BILLION) 44

FIGURE 13         IMMUNOTHERAPY DRUGS MARKET, BY APPLICATION,

2024 VS. 2029 (USD BILLION)      45

FIGURE 14         IMMUNOTHERAPY DRUGS MARKET, BY ROUTE OF ADMINISTRATION,

2024 VS. 2029 (USD BILLION)      45

FIGURE 15         IMMUNOTHERAPY DRUGS MARKET, BY END USER, 2024 VS. 2029 (USD BILLION)      46

FIGURE 16         IMMUNOTHERAPY DRUGS MARKET: REGIONAL SNAPSHOT              47

FIGURE 17         TECHNOLOGICAL ADVANCEMENTS IN ANTIBODY ENGINEERING TO DRIVE MARKET         48

FIGURE 18         US AND ANTIBODY DRUGS SEGMENT COMMANDED LARGEST MARKET

SHARE IN 2023  49

FIGURE 19         ANTIBODY DRUGS TO DOMINATE NORTH AMERICAN MARKET DURING STUDY PERIOD          50

FIGURE 20         IMMUNOTHERAPY DRUGS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES    51

FIGURE 21         IMMUNOTHERAPY DRUGS MARKET: PORTER’S FIVE FORCES ANALYSIS          59

FIGURE 22         INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF IMMUNOTHERAPY DRUGS        61

FIGURE 23         KEY BUYING CRITERIA FOR HOSPITALS AND LONG-TERM CARE FACILITIES           61

FIGURE 24         IMMUNOTHERAPY DRUGS MARKET: VALUE CHAIN ANALYSIS              62

FIGURE 25         IMMUNOTHERAPY DRUGS MARKET: SUPPLY CHAIN ANALYSIS              63

FIGURE 26         AVERAGE SELLING PRICE TREND OF IMMUNOTHERAPY DRUGS, BY KEY PLAYER             64

FIGURE 27         IMMUNOTHERAPY DRUGS MARKET: ECOSYSTEM MAP 67

FIGURE 28         PATENT APPLICATIONS FOR IMMUNOTHERAPY DRUGS

(JANUARY 2012–DECEMBER 2023)           70

FIGURE 29         NORTH AMERICA: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT        160

FIGURE 30         ASIA PACIFIC: IMMUNOTHERAPY DRUGS MARKET SNAPSHOT              184

FIGURE 31         REVENUE ANALYSIS OF KEY PLAYERS IN IMMUNOTHERAPY DRUGS MARKET (2021–2023)     227

FIGURE 32         MARKET SHARE ANALYSIS OF KEY PLAYERS IN IMMUNOTHERAPY DRUGS MARKET (2023)        228

FIGURE 33         IMMUNOTHERAPY DRUGS MARKET: COMPANY EVALUATION MATRIX

(KEY PLAYERS), 2023     230

FIGURE 34         IMMUNOTHERAPY DRUGS MARKET: COMPANY FOOTPRINT              231

FIGURE 35         IMMUNOTHERAPY DRUGS MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023           237

FIGURE 36         EV/EBITDA OF KEY PLAYERS    241

FIGURE 37         YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA

OF KEY PLAYERS           241

FIGURE 38         IMMUNOTHERAPY DRUGS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS          242

FIGURE 39         MERCK & CO., INC.: COMPANY SNAPSHOT (2023)           246

FIGURE 40         JOHNSON & JOHNSON SERVICES, INC.: COMPANY SNAPSHOT (2023)   252

FIGURE 41         F. HOFFMANN-LA ROCHE LTD.: COMPANY SNAPSHOT (2023)              257

FIGURE 42         ASTRAZENECA: COMPANY SNAPSHOT (2023)    263

FIGURE 43         PFIZER INC.: COMPANY SNAPSHOT (2023)         271

FIGURE 44         AMGEN INC.: COMPANY SNAPSHOT (2023)        275

FIGURE 45         NOVARTIS AG: COMPANY SNAPSHOT (2023)     279

FIGURE 46         ELI LILLY AND COMPANY.: COMPANY SNAPSHOT (2023)              283

FIGURE 47         SANOFI: COMPANY SNAPSHOT (2023)   288

FIGURE 48         BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT (2023)   293

FIGURE 49         GILEAD SCIENCES, INC.: COMPANY SNAPSHOT (2023)  300

FIGURE 50         TAKEDA PHARMACEUTICAL COMPANY LIMITED: COMPANY SNAPSHOT (2023)          304

FIGURE 51         TEVA PHARMACEUTICAL INDUSTRIES LTD.: COMPANY SNAPSHOT (2023)          307

FIGURE 52         ABBVIE INC.: COMPANY SNAPSHOT (2023)        310

FIGURE 53         GSK PLC: COMPANY SNAPSHOT (2023) 314

医療・医薬の最新記事8件